Proposal for change in the Board of Directors of ODI Pharma AB
Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting on November 19, 2024.
Malcolm Allan has extensive experience in senior positions within global companies and political campaigns. For the past three years, he has been serving as Vice President at Tilray Brands Inc. Prior to that, he was the Global COO for Havas Media and Managing Director for Prudential in London, UK. He holds a Bachelor of Arts with honors in Political Science and Economics from McGill University.
For more information about the Company, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: [email protected]
This information is information that ODI Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-30 15:41 CEST.
About ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.
